Online inquiry

IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13088MR)

This product GTTS-WQ13088MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MADCAM1 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_130760.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8174
UniProt ID Q13477
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13088MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4174MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ10616MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY3300054
GTTS-WQ3399MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aALB03
GTTS-WQ1893MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ15771MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ1407MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACA125
GTTS-WQ10606MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY3300054
GTTS-WQ5636MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP870
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW